Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 3/20 | 0.47 |
| ▸ | WNT3 | P56703 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685141 | 1.00 | SFRP1 (0.47) | SFRP1WNT3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8483131 | 0.91 | HTR2C (0.51) | SFRP1WNT3SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL70687 | 0.90 | HTR2C (0.53) | SFRP1WNT3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28166430 | 0.80 | MEN1 (0.51) | MEN1KMT2ACTSS | |
| SCHEMBL2683108 | 0.77 | ALDH1A1 (0.46) | CTSS | |
| SCHEMBL2683110 | 0.77 | ALDH1A1 (0.46) | CTSS | |
| SCHEMBL15338537 | 0.77 | ALDH1A1 (0.46) | CTSS | |
| SCHEMBL18343834 | 0.77 | APLNR (0.40) | — | |
| SCHEMBL29529651 | 0.77 | HTR2C (0.49) | SFRP1WNT3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3118862 | 0.76 | MEN1 (0.47) | MEN1KMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635562-B1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-09-03 | — | — | EP | disclosed |
| CN-103201274-B | Pyrrolidine derivatives used as cathepsin inhibitors | HOFFMANN LA ROCHE | 2014-08-20 | — | — | CN | disclosed |
| EP-2635562-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| CN-103201274-A | Pyrrolidine derivatives used as cathepsin inhibitors | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | CTSD, CTSV, CTSS | SFRP1 4430/4885WNT3 4747/4885SLC6A2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.